Your browser is no longer supported. Please, upgrade your browser.
TLSA Tiziana Life Sciences PLC daily Stock Chart
Tiziana Life Sciences PLC
Index- P/E- EPS (ttm)-0.14 Insider Own- Shs Outstand84.27M Perf Week-18.33%
Market Cap386.80M Forward P/E- EPS next Y-0.05 Insider Trans- Shs Float31.96M Perf Month33.59%
Income- PEG- EPS next Q- Inst Own13.22% Short Float0.50% Perf Quarter181.25%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.13 Perf Half Y399.35%
Book/sh-0.08 P/B- EPS next Y- ROA- Target Price- Perf Year220.98%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.62 - 12.17 Perf YTD325.00%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.09% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low609.42% ATR0.89
Employees8 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)50.04 Volatility8.78% 18.90%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.36 Prev Close4.59
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.26M Price4.37
Recom2.00 SMA20-6.51% SMA5027.18% SMA200151.06% Volume341,026 Change-4.79%
Dec-17-18Initiated Laidlaw Buy
Aug-11-20 04:00AM  
Aug-06-20 03:57PM  
Aug-05-20 11:00AM  
Aug-04-20 02:00AM  
Aug-03-20 02:00AM  
Jul-31-20 12:05PM  
Jul-30-20 11:31AM  
Jul-24-20 02:00AM  
Jul-20-20 10:17AM  
Jul-16-20 07:23AM  
Jul-15-20 06:34PM  
Jul-14-20 10:41AM  
Jul-10-20 01:41PM  
Jun-30-20 09:35AM  
Jun-29-20 03:12AM  
Jun-19-20 07:41AM  
Jun-18-20 01:50PM  
Jun-15-20 09:53AM  
Jun-04-20 02:00AM  
May-29-20 02:00AM  
May-22-20 02:00AM  
May-14-20 10:00AM  
May-11-20 02:00AM  
May-03-20 04:37AM  
Apr-27-20 09:21AM  
Apr-24-20 02:18PM  
Apr-09-20 02:00AM  
Mar-16-20 03:15PM  
Mar-12-20 10:07AM  
Mar-11-20 07:34PM  
Jan-21-20 12:06PM  
Jan-16-20 06:56AM  
Jan-10-20 09:08AM  
Jan-09-20 07:20AM  
Dec-24-19 11:39AM  
Dec-23-19 08:22PM  
Sep-16-19 07:44AM  
Sep-10-19 07:00AM  
Sep-04-19 07:00AM  
Jul-22-19 02:10AM  
Jul-01-19 04:24AM  
Jun-24-19 01:26PM  
May-28-19 07:00AM  
Apr-24-19 10:57AM  
Mar-20-19 07:46AM  
Dec-11-18 05:43PM  
Dec-03-18 03:29AM  
Nov-28-18 10:24AM  
Nov-23-18 12:11PM  
Nov-19-18 07:19PM  
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.